HELP THE PHILLY PI DELIVER UNBIASED, COMMUNITY-FOCUSED NEWS
The Philly PI relies on reader support to deliver crucial investigative reporting, breaking news, community safety updates, and transparent tech coverage. Independent journalism requires time, deep research, and absolute editorial freedom—free from paywalls, political influence, or corporate control. We cannot keep our newsroom running without you.
100% READER-FUNDED NEWSROOM
NO PAYWALLS OR CORPORATE CONTROL
KEEP INDEPENDENT JOURNALISM FREE FOR ALL
Not all dolphins live in the oceans. Some can be found swimming…
Hermit crab. Image via Wiki Commons. In the humid, coastal forests of…
Narwhals are among the strangest animals in the oceans. They’re like unicorns…
Disturb the dead and disaster may follow. Such is the pharaohs’ curse,…
Flow in the Colorado River has shrunk by about 20% since 2000,…
Still from footage of the reported new island at Williston. Credit: Facebook.…
South San Francisco-based biotech firm Lycia Therapeutics (LYCA) has successfully upsized and priced its initial public offering at $18.00 per…
The broader initial public offering market is currently playing a waiting game, with investors anticipating a blockbuster filing from Anthropic…
TCGX Acquisition Corp. II (TCXB), a stock-only special purpose acquisition company (SPAC), made a strong debut on the NASDAQ on…
RNAi-focused clinical-stage biotech City Therapeutics (CTY) has officially priced its upsized initial public offering at $18.00 per share, hitting the…
Iambic Therapeutics (IAM), a San Diego-based Phase 1 cancer biotechnology company, has priced its initial public offering at $16.00 per…
Biotechs Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are taking center stage this week as the only two…
Cambridge, Massachusetts-based clinical biotech firm City Therapeutics has set terms for its upcoming initial public offering on the NASDAQ under…
South San Francisco-based biotech firm TRex Bio (TRXB) has priced its initial public offering at $14.00 per share—the low end…
Sign in to your account